Switch theme
Sign up to access all valuation multiples
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
1998
32
LTM Revenue $47.8M
LTM EBITDA $9.7M
$129M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fennec Pharmaceuticals has a last 12-month revenue of $47.8M and a last 12-month EBITDA of $9.7M.
In the most recent fiscal year, Fennec Pharmaceuticals achieved revenue of $33.3M and an EBITDA of $3.4M.
Fennec Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fennec Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14.9M | $33.3M | XXX | XXX | XXX |
| Gross Profit | $1.0M | $14.0M | XXX | XXX | XXX |
| Gross Margin | 7% | 42% | XXX | XXX | XXX |
| EBITDA | -$8.8M | $3.4M | XXX | XXX | XXX |
| EBITDA Margin | -60% | 10% | XXX | XXX | XXX |
| Net Profit | -$16.6M | -$11.2M | XXX | XXX | XXX |
| Net Margin | -112% | -34% | XXX | XXX | XXX |
| Net Debt | $0.8M | $12.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Fennec Pharmaceuticals's stock price is CAD 7 (or $5).
Fennec Pharmaceuticals has current market cap of CAD 195M (or $136M), and EV of CAD 184M (or $129M).
See Fennec Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $129M | $136M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Fennec Pharmaceuticals has market cap of $136M and EV of $129M.
Fennec Pharmaceuticals's trades at 2.7x LTM EV/Revenue multiple, and 13.3x LTM EBITDA.
Analysts estimate Fennec Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Fennec Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $129M | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 38.4x | XXX | XXX | XXX |
| P/E | -446.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 6.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFennec Pharmaceuticals's NTM/LTM revenue growth is 20%
Fennec Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Fennec Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Fennec Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Fennec Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 124% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -138% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 39% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 48% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 88% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fennec Pharmaceuticals acquired XXX companies to date.
Last acquisition by Fennec Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Fennec Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Fennec Pharmaceuticals founded? | Fennec Pharmaceuticals was founded in 1998. |
| Where is Fennec Pharmaceuticals headquartered? | Fennec Pharmaceuticals is headquartered in Canada. |
| How many employees does Fennec Pharmaceuticals have? | As of today, Fennec Pharmaceuticals has 32 employees. |
| Who is the CEO of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's CEO is Mr. Jeffrey S. Hackman. |
| Is Fennec Pharmaceuticals publicy listed? | Yes, Fennec Pharmaceuticals is a public company listed on TSE. |
| What is the stock symbol of Fennec Pharmaceuticals? | Fennec Pharmaceuticals trades under FRX ticker. |
| When did Fennec Pharmaceuticals go public? | Fennec Pharmaceuticals went public in 2001. |
| Who are competitors of Fennec Pharmaceuticals? | Similar companies to Fennec Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's current market cap is $136M |
| What is the current revenue of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's last 12-month revenue is $47.8M. |
| What is the current EBITDA of Fennec Pharmaceuticals? | Fennec Pharmaceuticals's last 12-month EBITDA is $9.7M. |
| What is the current EV/Revenue multiple of Fennec Pharmaceuticals? | Current revenue multiple of Fennec Pharmaceuticals is 2.7x. |
| What is the current EV/EBITDA multiple of Fennec Pharmaceuticals? | Current EBITDA multiple of Fennec Pharmaceuticals is 13.3x. |
| What is the current revenue growth of Fennec Pharmaceuticals? | Fennec Pharmaceuticals revenue growth between 2023 and 2024 was 124%. |
| Is Fennec Pharmaceuticals profitable? | Yes, Fennec Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
